From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Addressing the disparities: The approach to the African American patient with multiple myeloma

Last Updated: Tuesday, May 14, 2024

This review offers an outline of disparities in multiple myeloma care at both biologic and non-biologic levels, barriers to clinical care, and best practices to ensure that African American patients receive equitable care. Disparities in incidence, timely diagnosis, access to treatment, clinical trial participation, and health-care utilization that negatively impacted outcomes for African American patients with multiple myeloma were identified.  

Blood Cancer Journal
Advertisement
News & Literature Highlights

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report

Advertisement
Advertisement